Women who inject drugs have been shown to have higher incidence of HIV and risk behaviours than men, but there are conflicting reports about hepatitis C virus (HCV) incidence. We systematically reviewed the literature to examine the female-to-male (F:M) HCV incidence in female and male persons who inject drugs (PWID), and also to explore the heterogeneity (i.e. methodological diversity) in these differences. We Our findings raise questions and concerns regarding sex differences with respect to the risk of HCV. Both behavioural and biological studies are needed to investigate causes and potential mechanisms as well as sex-specific prevention approaches to HCV infection.
interval (95% CI): 1.8%-3.3%) of the population aged 13 or older have reported any lifetime injection drug use. 7 The rate of current illicit drug use is higher for males than for females, and males are more likely than females to be current users of several different illicit drugs. As a result, more numbers of males are infected than females. 7 However, several studies have shown that injection practices of women, including higher rates of equipment and syringe sharing, women using injecting equipment following their male partners and being injected by others, may put them at higher risk. [8] [9] [10] [11] [12] In addition, women who inject drugs have been shown to have higher incidence of HIV and higher injection-related risk behaviours. [13] [14] [15] [16] HCV surveillance data generally show lower HCV detection rates among females compared to men. Viral hepatitis statistics and surveillance in 2013 in the U.S. reported 0.5 and 0.7 cases/10 000 among females and males, respectively. 17 HCV surveillance data in European
Centers of Disease Prevention reported the male-to-female ratio of 1.9 to 1 in 2013. 18 In Canada, from 1998 to 2004, the enhanced Hepatitis Strain Surveillance System found HCV detection rates per 100 000 people were 1.31 times (95% CI 1.09, 1.58) higher among males than among females, and sex-specific rate for HCV detection showed the same trend over the time. 19 The literature on HCV prevalence does not suggest differences between women and men. Hagan et al. 20 evaluated 58 studies that reported HCV prevalence in relation to biological sex. The crude and weighted odds ratio (OR) for the difference in HCV prevalence between males and females were 0.95 and 1.0, respectively (95% CI for weighted OR: 0.94, 1.07). Both surveillance data and studies of prevalence, however, are limited in the capacity of informing the overall burden and incidence of HCV due to challenges in case detection associated with asymptomatic infection, low reporting overall and resource limitations.
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For these reasons, prospective cohort studies, which assess newly or recently acquired infections systematically, offer the most reliable information on incidence of HCV infection. 22 HCV differences by sex in longitudinal studies of people who inject drugs (PWID) appear to be inconsistent upon brief review. In a retrospective cohort study, in Sydney, Australia, Micallef et al. 23 reported that women were less likely than men to become infected with HCV, whereas Maher et al. 24 in a prospective study found that women were significantly more likely to become infected. Two prospective studies, in Canada and Switzerland, in PWID found nonsignificant differences by sex. 25, 26 Other reports suggest a significantly higher incidence among female PWID compared to male PWID, including in San Francisco, The
Netherlands and China. 12, 27, 28 These discrepancies point to the need for more systematic analysis of studies of HCV infection differences between females and males who inject drugs.
We systematically searched the literature to explore the heterogeneity (i.e. methodological diversity) reported in HCV incidence rate between female and male PWID. We conducted a meta-analysis including studies that reported HCV incidence by sex or HCV incidence 
| METHODS

| Search strategies and study identification
Methods used to search and identify the target articles were based on the methodology described by Stern et al. 29 Briefly person-years of follow-up, incidence rate (with 95% CI) and F:M ratio (crude and adjusted effect size). In order to assess the quality of data reporting (selection bias, misclassification of exposure or outcome, and confounding due to noncomparability of the groups being compared), we used Newcastle-Ottawa Scale (NOS) for cohort studies. 
| Data synthesis and analysis
We extracted or calculated the crude and adjusted F:M ratio within the studies (Tables 1 and S We used incidence rate ratio calculator of Stata to compute confidence interval.
c
The effect size or CI is calculated. F:M IRR: Female-to-male incidence rate ratio. The incidence rate or CI is calculated.
e
The source of included studies is cited in supplementary documents as well.
T A B L E 1 (continued)
Adjusted rate ratios were used in the analysis where they were reported in the source studies with the goal of minimizing bias in the estimate of measured effect as described by Hagan et al. 32 We transformed the HCV incidence rate ratio into the natural logarithm.
Results are presented as rate ratios (converted from the natural logarithm; Table 2 ). Forest plots were created to show pooled estimates of incidence rate and 95% CIs by sex and F:M rate ratio. Using a randomeffects model, we estimated the overall ratio and in subgroups of geographic locations, type of collecting data, recruitment setting types and by model of analysing, types of effect size (if sex is included in adjusted model), NOS score and screening test (anti-HCV and/or RNA).
The results were sorted by the estimated mid-point of recruitment date (Figures 2 and 3) . Publication bias was evaluated using a funnel plot with Egger's bias indicator test.
Analyses were conducted using Stata version 13.1 (StataCorp LP, College Station, Texas USA) for data analyses using the metan command, and heterogeneity was assessed using the I 2 statistics. We used meta-regression to evaluate trend of F:M IRR over the time (the estimated mid-point of recruitment date).
| RESULTS
A total of 2393 reports published from 1989 through March 2015
were identified. Of these, 103 were determined to be eligible for full text assessment (Figure 1) . The cohort studies included overall had high NOS ratings, ranging from 7 to 9 (of 10). The characteristics of included studies (all the articles that reported the HCV incidence in PWID) are shown in Tables 1 and S. 1. We identified duplicate data from same cohorts (Table S. 2) based on matching cohort names, settings and geographic area; this was followed by comparing sample sizes, years of data collection and other study characteristics to select the most complete and informative report (cohorts) for final analysis.
Subgroups (Number of studies)
Incidence rate ratio (95% CI) In studies which recruited participants from community settings, In Canada and USA, the observed variability was due to chance only (sampling error) as both had I 2 of 0% (P>.42) with no time trend in results. Behavioural and social risks have been shown to differ between female and male injectors, 9, 12, 13, 16 and some studies that have investigated sex differences have found that some of these risk exposures can account for differences in HCV incidence. 8, 12, 37 In addition to differential behavioural risks, studies are needed to assess other potential causes and mediators, including biological and structural factors, that contribute to differential HCV risk. Biological factors that may contribute to increased susceptibility, oestrogen receptors and genetic variations in the oestrogen receptor gene (the oestrogen receptor 2 gene) are potential factors which might contribute to higher HCV incidence in females. 38 The natural history of HCV infection does differ significantly in females compared to males including higher rates of viral clearance, 39 reclearance after reinfection 40 and differences in response to HCV treatment for chronic HCV. 41, 42 Overall, a lack of information on sex-specific differences is the norm; we found that just over a third (34.5%) of studies on HCV incidence examined sex-related differences in HCV incidence. Further work should go beyond controlling for sex differences and begin to examine factors that contribute to differences, and especially higher risk in women.
Tests of heterogeneity
| DISCUSSION
These findings regarding incident HCV are in contrast to those seen with respect to prevalent HCV infection, where meta-analyses show prevalence parity among PWID. 20 Factors that can lead to differences in HCV infection measures, including in incidence and prevalence studies, include how HCV infection is measured, and how frequently. As women are significantly more likely to spontaneously clear HCV, 39, 43 variability in HCV testing interval in the different studies may also contribute to biased estimates of infection detection. 44 Spontaneous clearance of HCV also may explain differences in the rate ratios observed between clinical settings where monitoring may be more frequent and have the highest rate ratio (1.72) compared with prison (1.48) or community (1.24) settings (Table 2) . (Table 2) . Finally, we assessed the publication bias by looking at the symmetrical funnel plot (Figure 4 ), indicating that there is no publication bias for the F:M ratios (Egger's test P=.736).
Globally, sexual differences in burden of HCV infection are not well studied. While our results show that there is a differential in HCV acquisition, in absolute numbers, among PWID more males are HCVinfected than females, due to the higher prevalence of injecting, 7 and lower HCV clearance. 39 Nevertheless, there is a need to assess and identify mechanisms for sex-related differences. Biological factors may contribute to differences in HCV susceptibility by sex, but potential mechanisms have not been studied. Certainly, other data show that women have different biological responses to HCV: female PWID have higher rates of spontaneous clearance and reclearance after reinfection 39,40 than men, as well as lower rates of HCV-associated liver disease and mortality. 45 Behavioural and social factors, however, pose the most proximal point for interventions to reduce sex-related differences, as many studies have shown that females who inject drugs have significantly higher HCV-associated risk exposures than males. 8, [10] [11] [12] Behavioural, social and structural factors play an important role in transmission of HCV and other infections such as HIV, and these are likely to differ by country and region, where cultural, social and political factors may differentially impact risk by sex. Sex-based interventions are under-implemented and may have potential to contribute to reducing some of the risk differential between male and female PWID.
Studies show that female PWID often face significant stigma, leading to lower participation in harm reduction services. 46, 47 In addition to behavioural interventions, further integration of biomedical prevention especially targeting women is needed. 48 Opiate agonist therapy and needle and syringe programmes are proven, safe and effective interventions to reduce HCV infection, 32, 49 and new sex-based approaches should be explored with the goal of reducing disparities in HCV infection rates. As with many meta-analyses, especially of observational research, findings from this analysis reveal gaps/need for more research in the area. 50 Future investigations to assess mechanisms, mediators and moderators of the differences in HCV incidence between women and men will inform public health practice and approaches to prevention. 
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